GrayBug to Present at the 6th Annual Conference of the Arnold and Mabel Beckman Initiative for Macular Research


January 9, 2014 – GrayBug is pleased to announce that it has been invited to present at the 6th Annual conference of the Arnold and Mabel Beckman Initiative for Macular Research (BIMR) at the Beckman Center of the National Academies of Science and Engineering on January 23-25, 2014, in Irvine, CA.

About the BIMR

Through a generous grant from the Arnold and Mabel Beckman Foundation, the Beckman Initiative for Macular Research (BIMR) brings together outstanding scientists, engineers, medical researchers, and clinicians — all focused on a common goal: developing a better understanding of atrophic macular degeneration.

Related News

Press release

Joint Statement on Retina Clinical Trials and COVID-19

To our Colleagues in the Retina Clinical Trials Community: We all take the health and safety of patients, healthcare providers, and our local communities very seriously, and the ongoing pandemic is challenging healthcare delivery and Read more…

Press release

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months

REDWOOD CITY, Calif., March 18, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today announced the early closing of Read more…

Press release

Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual Meeting

REDWOOD CITY, Calif., February 28, 2020 – Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today presented pre-clinical study results for GB-401, a novel injectable Read more…